Compare ING Groep NV (ING) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Zoetis Inc — how do they compare? ING Groep NV trades at $35.65 (market cap $101.22B), while Zoetis Inc trades at $73.37 (market cap $31.14B). The key difference: ING Groep NV is far larger — about 3.3× Zoetis Inc's market cap, and ING Groep NV pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| ING | ZTS | |
|---|---|---|
Market Cap | $101.22B | $31.14B |
Sector | Financials | Health |
52-Week High | $35.92 | $156.76 |
52-Week Low | $23.66 | $71.91 |
Dividend Yield | 3.73% | 2.81% |
Enterprise Value | — | $38.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $35.66, up 1.19% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 forecast. Revenue growth is steady, reaching $22.90B in 2025, and the company recently raised its 2026-2027 outlook, driven by robust net interest income and lending growth. A dividend of $0.46 per share is scheduled for payment on August 17, 2026.
The outlook for ING is positive, supported by upward earnings revisions, a favorable valuation with a P/E of 13.24, and institutional bullishness. Key risks include persistent negative operating cash flows and sensitivity to interest rate changes. The stock's momentum and fundamental strength present a compelling case for growth-oriented investors, though cash flow trends warrant monitoring.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
